4.7 Article

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma

Journal

Publisher

MDPI
DOI: 10.3390/ijms22031341

Keywords

HDAC6; bortezomib-resistance; HDAC6-selective inhibitor; bortezomib; carfilzomib; multiple myeloma; LMP2; combination therapy

Funding

  1. Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology [2018R1A6A1A03023718, 2019R1I1A1A01058601]
  2. National Research Foundation of Korea [2019R1I1A1A01058601] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

The HDAC6-selective inhibitor A452 has been shown to overcome bortezomib resistance in multiple myeloma by decreasing the activation of resistant markers and synergistically inhibiting cancer cell growth when used in combination with other drugs. This discovery highlights the potential of A452 as a promising therapy for bortezomib-chemoresistant multiple myeloma patients.
Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance in MM. We show that HDAC6-selective inhibitor A452 significantly decreases the activation of BTZ-resistant markers, such as extracellular signal-regulated kinases (ERK) and nuclear factor kappa B (NF-kappa B), in acquired BTZ-resistant MM cells. Combination treatment of A452 and BTZ or carfilzomib (CFZ) synergistically reduces BTZ-resistant markers. Additionally, A452 synergizes with BTZ or CFZ to inhibit the activation of NF-kappa B and signal transducer and activator of transcription 3 (STAT3), resulting in decreased expressions of low-molecular-mass polypeptide 2 (LMP2) and LMP7. Furthermore, combining A452 with BTZ or CFZ leads to synergistic cancer cell growth inhibition, viability decreases, and apoptosis induction in the BTZ-resistant MM cells. Overall, the synergistic effect of A452 with CFZ is more potent than that of A452 with BTZ in BTZ-resistant U266 cells. Thus, our findings reveal the HDAC6-selective inhibitor as a promising therapy for BTZ-chemoresistant MM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available